oxelumab

{{One source|find=Oxelumab|date=January 2024}}

{{Short description|Monoclonal antibody}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 458269218

| type = mab

| image =

| alt =

| mab_type = mab

| source = u

| target = OX-40 ligand

| tradename =

| Drugs.com =

| MedlinePlus =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category=

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 1186098-83-8

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 67GFR7JCMN

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| ATC_prefix = none

| ATC_suffix =

| PubChem =

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| C=6424 | H=9920 | N=1704 | O=2014 | S=42

}}

Oxelumab is a human monoclonal antibody designed for the treatment of asthma.{{cite web|title=Statement On A Nonproprietary Name Adopted By The USAN Council: Oxelumab|publisher=American Medical Association|url=http://www.ama-assn.org/resources/doc/usan/oxelumab.pdf |archive-url=https://web.archive.org/web/20130512162542/http://www.ama-assn.org/resources/doc/usan/oxelumab.pdf |archive-date=12 May 2013 |url-status=dead}}

Oxelumab was developed by Genentech and co-developed by Roche.